Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA

López, Yuly; Tato, Marta; Gargallo-Viola, Domingo; Vila, Jordi; Zsolt, Ilonka

doi:10.1016/j.ijantimicag.2020.106082

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 The reason being that, Ozenoxacin is a not a substrate whereas other quinolones are a substrate for efflux pumps like MepA and NorA, commonly found in Gram-positive bacteria. 22…”

Section: Mechanism Of Actionmentioning

confidence: 99%

Ozenoxacin: A novel topical quinolone

Shirsat¹,

Shah²,

Trailokya³

2022

IJCED

View full text Add to dashboard Cite

The burden of dermatological conditions is huge on the global health accounting for 44.1 million DALYs worldwide. Impetigo is a highly contagious bacterial infection with 2.5 time’s greater likelihood in pediatrics (12.3%) than in adults (4.9%). Micro-organisms causing impetigo include bacteria like or both. The management of Impetigo is with topical and systemic antimicrobial agents. Topical antimicrobial resistance is on the rise in patients with Impetigo. Therefore, there is clearly a need for newer antimicrobials having different mode of action and showing good activity against non-responding strains in the management of impetigo. Ozenoxacin is a novel, topical quinolone with a good safety and tolerability profile in the management of Impetigo. The authorizing bodies namely USFDA, European Medical Agency, and DCGI have approved the use of Ozenoxacin 1% cream for the topical treatment of impetigo due to in adult and pediatric patients 2 months of age and older.

show abstract

“…3 The reason being that, Ozenoxacin is a not a substrate whereas other quinolones are a substrate for efflux pumps like MepA and NorA, commonly found in Gram-positive bacteria. 22…”

Section: Mechanism Of Actionmentioning

confidence: 99%